These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
875 related articles for article (PubMed ID: 36854505)
1. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides Voutsadakis IA; Stravodimou A Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505 [TBL] [Abstract][Full Text] [Related]
2. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264 [TBL] [Abstract][Full Text] [Related]
3. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Cerrato A; Morra F; Celetti A J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting and patient selection for cancers with homologous recombination defects. Talens F; Jalving M; Gietema JA; Van Vugt MA Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306 [TBL] [Abstract][Full Text] [Related]
6. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390 [TBL] [Abstract][Full Text] [Related]
7. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Watkins JA; Irshad S; Grigoriadis A; Tutt AN Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers. Huang CC; Tsai YF; Liu CY; Lien PJ; Lin YS; Chao TC; Feng CJ; Chen YJ; Lai JI; Phan NN; Hsu CY; Chiu JH; Tseng LM Ann Surg Oncol; 2022 Jun; 29(6):3578-3590. PubMed ID: 35226219 [TBL] [Abstract][Full Text] [Related]
13. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589 [TBL] [Abstract][Full Text] [Related]
14. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related]
15. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669 [TBL] [Abstract][Full Text] [Related]
17. The DNA damaging revolution. Cetin B; Wabl CA; Gumusay O Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228 [TBL] [Abstract][Full Text] [Related]
18. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib. McCann KE Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451 [TBL] [Abstract][Full Text] [Related]
19. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Gupta T; Vinayak S; Telli M Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381 [TBL] [Abstract][Full Text] [Related]
20. Somatic mutations in four novel genes contribute to homologous recombination deficiency in breast cancer: a real-world clinical tumor sequencing study. Huang Y; Qiu Y; Ding L; Ren S; Jiang Y; Luo J; Huang J; Yin X; Fu S; Zhao J; Hu K; Liao J J Pathol Clin Res; 2024 Mar; 10(2):e12367. PubMed ID: 38504382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]